Trial Profile
A Phase 1 Study of BLZ-100 Administered by Intravenous Injection in Subjects With Soft Tissue Sarcoma Undergoing Surgery
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 03 Jun 2016
Price :
$35
*
At a glance
- Drugs Tozuleristide (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors Blaze Bioscience
- 24 May 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 24 May 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 18 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.